BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Benzinga · 3d ago
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.